The Role of Immune Correlates and Surrogate Markers in the Development of Vaccines and Immunotherapies for Plague
2012
Understanding Vaccines and Treatments for Plague
publication
Evidence: moderate
Author Information
Author(s): E. D. Williamson
Primary Institution: Biomedical Sciences Department, Defence Science & Technology Laboratory
Hypothesis
Can immune correlates and surrogate markers help predict the efficacy of vaccines and therapies for plague?
Conclusion
Identifying immune correlates of protection is crucial for developing effective vaccines and therapies against plague.
Supporting Evidence
- Plague is still present in endemic regions and results in approximately 3,000 reported cases each year.
- The rF1/V vaccine has shown protective efficacy in various animal models against plague.
- Identifying immune correlates of protection can help bridge the gap between nonclinical and clinical vaccine development.
Takeaway
Scientists are trying to find ways to measure how well vaccines work against plague by looking at the immune response they create.
Methodology
The paper reviews existing literature on immune responses and vaccine efficacy in animal models.
Limitations
Clinical efficacy studies for plague are not feasible due to ethical and practical reasons.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website